WAVE Life Sciences had a table at the Huntington’s Disease Society of America (HDSA) Convention in Boston last month and I spoke with a rep for quite awhile. It’s very exciting what they are doing for Huntington’s disease (HD).
“We have designed stereopure oligonucleotides to selectively target the mutant HTT allele to lower the production of mHTT protein while leaving healthy HTT protein relatively intact.” https://www.wavelifesciences.com/
Huntington’s disease (HD) is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical and mental abilities usually during their prime working years and has no cure. http://www.hdsa.org
A little bit of information: We all have two Huntingtin genes; one from your father, one from your mother. Say, you have a CAG repeat of 42 from your father and a CAG count of 17 from your mother.
The drug WAVE life Science is conducting clinical trials on, Phase 1b/2a, only lowers the mutated Huntingtin gene and leaves the healthy one alone.
WAVE is currently enrolling adults with early manifest Huntington’s disease (HD) who carry a SNP at the rs362307 (“SNP1”) location for a Phase 1b/2a clinical trial.
WAVE is currently enrolling adults with early manifest Huntington’s disease (HD) who carry a SNP at the rs362331 (“SNP2”) location for a Phase 1b/2a clinical trial.
We Can Never Lose HOPE…………….